Patents Current Affairs

Indian Pharma companies rank 19th in Biopharmaceutical Competitiveness & Investment (BCI) Survey

Indian pharmaceutical companies have ranked low at 19th position with an overall score of 59 out of 100 among in the Biopharmaceutical Competitiveness & Investment (BCI) Survey.

The survey of 28 countries was commissioned by the Pharmaceutical Research and Manufacturers of America and executed by the Pugatch Consilium. It was third edition of survey.

How Survey was undertaken?

  • Five metrics were used to determine rankings of countries. They are (i) scientific capabilities and infrastructure; (ii) clinical research conditions and framework; (iii) regulatory system; (iv) market access and financing; and (v) effective intellectual property protections.
  • It had looked at biomedical innovation and its influencers, like intellectual property protection for investments in the pharmaceutical sector.
  • It had categorized countries into two groups viz. mature markets like UK US, and Germany, and newcomers like China, India and Brazil.

Key Highlights of Survey

  • Mature markets provide advanced intellectual property protection, highly streamlined regulatory framework and favourable tax conditions with some exceptions.
  • India, along with China, Argentina, Colombia, Russia, Turkey and Brazil based on their overall score were labelled as trailing markets.
  • Singapore which has placed in the newcomers category with a score of 85 is only a point behind the US, which is a mature market.
  • India scores low on almost all metrics except in the clinical research conditions and framework and scientific capabilities and infrastructure.
  • India’s IP regime, including Section 3(d) of IP Act requiring biopharmaceutical inventions to show ‘enhanced efficacy’, continues to affect its investment environment.

Tags:

Union Government opens Tatkal like channel to speed up patent grant process

Union Government has opened a special Tatkal like window to expedite examination process of patent applications by start-ups as well as of entities choosing India for filing the first patent.

In this regard, the Department of Industrial Policy and Promotion (DIPP) has as amended patent rules.

Under the new rules

  • Union Government is aiming to reduce the time frame for the grant of patents to 18 months from the present 5-7 years by March 2018.
  • It also seeks to popularise India as a patent filing hub so that more companies file applications in India.
  • The Controller General of Patents Designs and Trademarks (CGPDT) will only take up a limited number of applications under the fast-track route in one year.
  • Applicants can opt for the Expedited Examination Route if they have chosen India as International Preliminary Examining Authority or International Searching Authority.
  • The expedited route is also applicable to all those entities qualifying as a start-up as per the definition for start-up provided in the Patent Rules.

The new rules were made as per the India’s first National Intellectual Property Rights (IPR) policy which was unveiled earlier in May 2016. The policy seeks to focus on issues like expediting approval processes involving patents or trademarks and consolidating institutional mechanisms to create a robust IPR eco-system.

Tags:

123